BMS registers observational LUNIS study of Reblozyl in lower-risk MDS patients in GermanyNov 6Weekly roundup, 3 itemsBristol Myers Squibbluspatercept
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
BMS: Reblozyl label supplement approved; GLORY CAR-T trial and BMS-986485 Phase 1 postedOct 22Weekly roundup, 4 itemsBristol Myers Squibbliso-celUpdated
Bristol-Myers Squibb registers observational study of first-line Reblozyl in lower-risk MDSAug 7Trial updateBristol Myers Squibbluspatercept
Geron reports Q2 2026 results as RYTELO revenue climbs to $57.5 millionAug 6Quarterly updateGeron Corporationimetelstat
Bristol Myers Squibb raises 2026 guidance, cites pipeline progress across four programsJul 30Quarterly updateBristol Myers Squibbluspatercept
BMS week: two label updates, new luspatercept CKD trial, pulmonary fibrosis study registeredJul 24Weekly roundup, 6 itemsadagrasibBristol Myers Squibb
BMS posts PRIME-HCC results; adds SOTYKTU label update, Phase 3 lung trialJul 2Weekly roundup, 7 itemsBristol Myers Squibbcisplatin